Detecting early stage lung adenocarcinoma using imaging and biopsy markers
Official title: Integrating imaging and biopsy-derived molecular markers for the pre-surgical detection of indolent and aggressive early stage lung adenocarcinoma
Funded at Boston University Medical Campus · NIH-10885188 · Data updated 2026-11-12
This study is looking to help doctors find early signs of lung adenocarcinoma more accurately by using special imaging and genetic information from biopsies, so they can better understand how aggressive the tumors are and create more personalized treatment plans for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 10, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $607,822 |
| NIH project number | 5R01CA275015-02 |
| Project ID | NIH-10885188 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early stage lung adenocarcinoma who are scheduled for surgical treatment.
✕Less likely to help
Patients with advanced lung cancer or those who are not candidates for surgery may not benefit from this research.
What this research studies
This research aims to improve the detection of early stage lung adenocarcinoma by integrating advanced imaging techniques with molecular markers derived from biopsies. The approach focuses on identifying whether tumors are aggressive or indolent before surgical intervention, which could help tailor treatment plans more effectively. By developing and validating a model that combines radiomic and gene expression biomarkers, the research seeks to provide more accurate predictions of tumor behavior using limited tissue samples. This could lead to better management of lung cancer and reduce unnecessary treatments.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for lung cancer patients, improving outcomes and reducing unnecessary procedures.
How similar studies have gone: Previous research has shown promise in using imaging and molecular markers for cancer detection, suggesting that this integrated approach could be effective.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Lenburg, Marc Elliott — Boston University Medical Campus
- Study coordinator: Lenburg, Marc Elliott
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.